Trillium Therapeutics Reports Annual Financial and Operating Results
11 mars 2019 17h09 HE
|
Trillium Therapeutics Inc.
Positive data from the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF and ASH 2018 meetingsEncouraging signals of activity and tolerability data...
Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
08 mars 2019 18h37 HE
|
Trillium Therapeutics Inc.
TORONTO, March 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
22 févr. 2019 09h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
21 févr. 2019 16h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting
03 déc. 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results
14 nov. 2018 07h00 HE
|
Trillium Therapeutics Inc.
Positive clinical update on the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF meetingPositive clinical update on the intravenous trial of TTI-621...
Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences
28 sept. 2018 07h00 HE
|
Trillium Therapeutics Inc.
Data from intralesional trial in mycosis fungoides/Sézary syndrome patients continue to show promise, with rapid reductions in CAILS scores in the majority of patients and preliminary evidence of...
Trillium Therapeutics to Present at Upcoming Investor Conferences
27 sept. 2018 07h00 HE
|
Trillium Therapeutics Inc.
TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
12 sept. 2018 07h00 HE
|
Trillium Therapeutics Inc.
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target ConferenceUpdated data from the TTI-621 intralesional trial in patients with mycosis...
Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
30 août 2018 09h30 HE
|
Trillium Therapeutics Inc.
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...